EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer

Current Oncology

Volumn 19, Issue 2, 2012, Pages 1-8

  Kamel Reid, S ^a   Chong, G ^b   Ionescu, D N ^c   Magliocco, A M ^d   Spatz, A ^b   Tsao, M ^a   Weng, X ^e   Young, S ^c   Zhang, T ^a   Soulieres, Denis ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Epidermal growth factor receptor; Erlotinib; Gefitinib; Genetic testing; Non small cell lung cancer

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ASSAY; EPIDERMAL GROWTH FACTOR RECEPTOR 1 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 10 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 11 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 12 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 13 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 3 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 4 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 5 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 6 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 7 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 8 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 9 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE GENE; EXON; GENE DELETION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; MUTATOR GENE; PROCESS OPTIMIZATION; RECEPTOR GENE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

EID: 84859458169     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.862     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2007;57:43-66.
2. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase iii study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
3. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase iii study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24.
4. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase iii trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-18.
5. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
7. Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/ F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005;65:8968-74.
8. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall- cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501.
9. Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (cbdca) plus paclitaxel (txl) in non-small cell lung cancer (nsclc) patients (pts) with efgr mutations: a phase iii study (002) by North EastJapan Gefitinib Study Group [abstract 8016]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst_detail_view&confID=65 &abstractID=31299; cited February 3, 2012]
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
11. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
12. Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the efgr signaling pathway and their relationship to efgr tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009;4:e4576.
13. Pao W, Miller V, Zakowski M, et al. egf receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
14. Paez JG, Jänne PA, Lee JC, et al. EFGR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
15. Paz-Ares L, Soulières D, Melezínek I, et al. Clinical outcomes in non-small-cell lung cancer patients with EFGR mutations: pooled analysis. J Cell Mol Med 2010;14:51-69.
16. Frayling IM. Methods of molecular analysis: mutation detection in solid tumours. Mol Pathol 2002;55:73-9.
17. Nollau P, Wagener C. Methods for detection of point mutations: performance and quality assessment. ifcc Scientific Division, Committee on Molecular Biology Techniques. Clin Chem 1997;43:1114-28.
18. Parsons BL, Heflich RH. Genotypic selection methods for the direct analysis of point mutations. Mutat Res 1997;387:97-121.
19. Milbury CA, Li J, Makrigiorgos GM. pcr-based methods for the enrichment of minority alleles and mutations. Clin Chem 2009;55:632-40.
20. Gocke CD, Benko FA, Kopreski MS, Evans DB. Enrichment methods for mutation detection. Ann N Y Acad Sci 2000;906:31-8.
21. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic efgr mutations. J Clin Oncol 2008;26:2442-9.
22. Zhou C, Wu YL, Chen G, et al. Updated efficacy and qualityof- life (qol) analyses in optimal, a phase iii, randomized, open-label study of first-line erlotinib versus gemcitabine/ carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (nsclc) [abstract 7520]. J Clin Oncol 2011;29:. [Available online at: ht tp://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&conf ID=102&abstractID=81408; cited February 3, 2012]
23. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (ct) in advanced non-small cell lung cancer (nsclc) patients (p) with epidermal growth factor receptor (efgr) mutations: interim results of the European Erlotinib Versus Chemotherapy (eurtac) phase iii randomized trial [abstract 7503]. J Clin Oncol 2011;29:. [Available online at: ht tp://www.asco.org/ASCOv2/Meet ings/abst racts? &vmview=abst_detail_view&conf ID=102&abstract ID=78285; cited February 3, 2012]
24. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26:1742-51.
25. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-62.
26. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinibsensitizing EFGR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
27. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EFGR mutants. PLoS Med 2005;2:e313.
28. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
29. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077-80.
30. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
31. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reactionbased detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403.
32. Author reply to: Marchetti A, Felicioni L, Buttitta F. Assessing EFGR mutations. N Engl J Med 2006;354:526-8.